JFIFPhotoshop 3.08BIM?Immunotherapy Addition Demonstrates Sustained Survival Benefits720260529PSCIENMAGUAuthorImmunotherapy Addition Demonstrates Sustained Survival Benefits in Long-Term Follow-Up of NRG Oncology Trial for Advanced or Recurrent Endometrial Cancer Science@https://scienmag.com/immunotherapy-addition-demonstrates-sustain© 2026 Sciencehttps://scienmag.com/In a groundbreaking advancement for the treatment of advanced and recurrent endometrial cancer, recent prolonged follow-up results from the NRG Oncology GY018 phase 3 trial have reinforced the survival benefits of incorporating pembrolizumab, an immunotherapy agent, alongside standard chemotherapy. Initially reported immature overall survival data had suggested a promising improvement, but with extended monitoring, these […]ScienceCanCancerCancer3carboplatin and paclitaxel chemotherapy limitations4immune checkpoint inhibitors in gynecologic oncology-immunotherapy for advanced endometrial cancer1long-term survival benefits in endometrial cancer.mismatch repair status impact on immunotherapy NRG Oncology GY018 trial results*PD-1 pathway targeting in cancer treatment*pembrolizumab and chemotherapy combination,phase 3 clinical trial in endometrial cancerrole of MMR deficiency in5treatment strategies for recurrent endometrial cancerC    !'"#%%%),($+!$%$C   $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$"? !1AQ"2aq#BR3Cs45br8!1AQ"q23Ra4B#cr ?5|p-jY1^ 8fDDyB9sSeMVϙl3c1߯46=x%s\mVW--!"a*e?v+?\ݿ_r5j)aRE$G`VsS9X`xz|o>u ziR.B<27;T4|Neh i{)CjGcV9a5S|k9,-n% [ږ3{?iV̜:.7:Lg "7 UջAv%$NpMh/ձ+* 0#AHu8չDA)|+e]cl]tx' 1ZF4iwbLrfik^gcMt!~2iV ұxVuD:fU8V5Ā58B~! kK^ʨcҮm-%@Un=-*v?|0cci&څ;,݈bpsD̒`$g Q;Hĉ3}\$ر5p3<^n$H*$c4'$@2qQ%꥞C{+-2Jȷ5@]0׭M>tRHmRi#gS}7F+#!!x_):5J*W,Mӄvy4|d` 8?*ieú}a{ $ FOʜ̖b5.\꧚;ǩZM 2y B{c*qԾ)yk'pM3ax48$;7ytOn7wI'=-rcw2ڦʚaPyte][cF2ר#WӵO툄8gR-g]Vsѿm[УtoKs&qYR[ycչcTiO:R[O?N yjAe:jW\5C r_;|iK/+o}}jikú$A'?\SBDctj(qjgK 'Q]͠zFFjۭua+NNȻf*p%Vup܉+FBѳ5m޸vd߰:EreRCun ssbU*K~BGp*@޳lY&̨h> 2p IƏ] QNZn|<Ҵ929x>'Af;=,q(Ď .-LAq=}p]lҫvKx:[;/pTH2~*<>4$[F`^[l3Գ?^US{2ʎž_G:ϭ=8=HË́84pUQu*[JOk,qH?J PDOoEjYÝ܏,;$Hꀌ4861fTu1U]u[I,qʋ3l U;39#qNj6~כt%~1. z5߉dt; ?"|}R..~f6(Q@Ҷpseag`nZ FkqYGS? O$|x:HZCIQh\d") ew e8 yirC<.#]@#'=1}< A7 |6Z沺I9w/7Yk; ӆ?NtLچm|0OcBjHcǃ~Ke{687, sq/|StFֆ~cZ"f9V*[p=zd]hp[ñtU-usfdB:Wq <eFavo6f"NaC LlZoTxaA?[iY! &u >++s0H;aOb4c4DcHGwt_2SPxJ2ZN![+ՖHM2`.^qkt.BL!ry*I_ '>kZ\-x>L+mѷw6q Ě^Av"}mǧO/ǦR*ܬ|q<2@r-d7H%L+߯Pi$6 c_Gh)xZSFz?zpk۹ ?8YRkW2o}}u~l*,iq ap 7IiOI%J bO2 {"٣- t ;?R Q+ E+fGj rf7*)%w;OQ泼_dbjڊy4[vM XqH3鲮2bwb>?*=Mp@bOs2m%ڰ$3dxjp[:)[iA-ˏ34+%|卣oQ1)'5&L K+NMgดJfJS%-)Z[4Ojqir< x;: H]E!hiSİ}#>OJӤEy7":XҎ{(-y'}9f4KWPY-K-t&1CjP9 ~)J?UQ9cG}\j1 Ri=r;SNoۓZ3Z+5x*)\}|*,2S0 0|3UG9 l/Vy31)= P/@4Ґ)ʅ'qD]ZBz-hu1pŨa|Ǹ\+,e(v46V֒҆*$CDۻ Ss+T:7fR)fCHA=klEr\>y>+H%]) q榔^]?4⯭KRrSRJTR釚Jo/\Q5֩gj^' 5д~+l MJќg&$ հHQ=*g CGKte]c ĐZ.vXQqD=-+}#Eu\F8{PVW]Lt}N2E}iM i2C!lmA*O*pJڔ[ʌT=nv^Ε񻃀:H~)lqrmA4ψ>|+/t9צMRt/30sݲOZHW:Llҹ5ɶ2C橚Ciym s(;orкࣚfF.vZx\Y$'s pn _F^șDn+AqV sYAm: isbŐ7) y_T{) nH7'AWr^+Fhu83571il/1ȢM-N8ٍ(3JZtېG./vv]aQ'jߒ9{'bo)]bV"N!a* fU1x#-$d0n6ߔ\*ALDN;'$|/ċ/5,Կ d)r ژhJU-;zؽ2م~^ztIĐ>4+;$y`f!@5 {u2aƥ Ç[-)l,ޫ/I"hz3HiFiW+kv?jU-dW^g[O-iai,)ƥ M9^ibN3yP{d+XAֽvF8}vF o,4I+/Ͼ&JU(Qʂ*Ure/W^ר@RyCR'R*P+-TM2PJD;u+}êJHoÀ5OSu?+m^ChכʥJ?*\ԩTR4RwjR=xTzxԤAV;ԩEU„ @aRJ